BMO Capital Maintains Outperform on Merck & Co, Raises Price Target to $142

ميرك اند كو

Merck & Co., Inc.

MRK

0.00

BMO Capital analyst Evan David Seigerman maintains Merck & Co (NYSE: MRK) with a Outperform and raises the price target from $135 to $142.